Contract research, development, and manufacturing organisation (CRDMO) Syngene International is enhancing its commercial biologics facility (Unit 3) in Bengaluru by adding a GMP-compliant bioconjugation suite. The new capability will provide end-to-end services for antibody-drug conjugates (ADCs), spanning discovery, process development, and GMP manufacturing. Syngene expects the facility to become operational within the current financial year.
Integrated Capability to Accelerate ADC Development
The OEB-5-rated suite will enable both monoclonal antibody (mAb) production and GMP bioconjugation at a single site, accelerating ADC development timelines. It will also support a broad range of advanced conjugates and related modalities, allowing Syngene to offer comprehensive solutions for diverse therapeutic programs.
Alex Del Priore, Head – LM CDMO, Syngene International, stated, “By integrating bioconjugation capabilities with our commercial-scale biologics, payload, and linker production units in Bengaluru, we can significantly compress development timelines and offer a unique, end-to-end pathway from early discovery through GMP manufacturing.”
Leveraging Expertise for Clinical and Commercial Programs
Building on over a decade of experience in ADC discovery, Syngene has established expertise in handling high-potency payloads, linkers, and mAbs within well-equipped GMP-compliant facilities. The expanded biologics suite is designed to support clinical programs while laying the groundwork for future commercial-scale ADC capabilities.
Comprehensive Support for Development Programs
As reported by thehindubusinessline.com, in addition to GMP manufacturing, the laboratories will provide process development, analytical characterization, and scale-up support for both early- and late-stage programs, ensuring a seamless pathway from discovery to commercial production.
